Dow Down1.40% Nasdaq Down1.59%

Vanda Pharmaceuticals, Inc. (VNDA)

10.16 Down 0.22(2.12%) 4:00PM EDT
ProfileGet Profile for:
Vanda Pharmaceuticals, Inc.
2200 Pennsylvania Avenue NW
Suite 300E
Washington, DC 20037
United States - Map
Phone: 202-734-3400
Fax: 202-296-1450

Index Membership:N/A
Full Time Employees:56

Business Summary 

Vanda Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development and commercialization of pharmaceutical products. Its product portfolio includes HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder; Fanapt, a product for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Vanda Pharmaceuticals, Inc.

Corporate Governance 
Vanda Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Sep 1, 2014 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 10; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Mihael H. Polymeropoulos M.D., 54
Founder, Chief Exec. Officer, Pres and Director
Mr. James Patrick Kelly , 48
Chief Financial Officer, Principal Accounting Officer, Sr. VP, Treasurer and Sec.
Dr. Paolo Baroldi M.D., Ph.D., 63
Chief Medical Officer and Sr. VP
Mr. Vincent J. Milano , 50
Director, Chairman of Compensation Committee and Member of Audit Committee
Mr. Gunther Birznieks ,
VP of Bus. Devel.
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders